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Dermatomyositis (DM) is characterized by pathognomic cutaneous manifestations (heliotrope rash, periorbital edema,
Gottron’s papules) and proximal muscle weakness. In this paper, I will present the case of a 48-year-old female patient
whose dermatomyositis was initially diagnosed as vasculitis. Following the patient’s inadequate response to corticosteroid
treatment, clinical and radiologic examinations were performed, showing inoperable gallbladder adenocarcinoma.
Although initial chemotherapy led to regression, the dermatomyositis developed an independent course with new
pathological changes leading to the progression of the disease. I will also present an overview of case reports in English
published so far. Gallbladder carcinoma should be added to the list of malignancies with dermatomyositis and has to be
excluded by relevant investigation in women.
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Dermatomyositis (DM) is an uncommon inflammatory
myopathy characterized by pain and weakness in the
proximal muscles and cutaneous manifestations. The skin
findings of DM include scaly violaceous papules and
plaques overlaying the bony prominences of the hands
(Gottron’s papules), violaceous patches on the periorbital
skin (heliotrope eruption), photodistributed poikiloderma-
tous patches and plaques, scaly plaques on the scalp and
lateral thighs, periungual telangiectasia, and ragged cuti-
cles [1]. Malignancies may occur before, simultaneously
with or after the onset of DM [2]. The most common
malignancies associated with DM are ovarian and lung
cancer [3]. The pathogenesis of paraneoplastic DM is
still relatively unknown, although there is some evi-
dence to support the involvement of humoral and cell-
mediated immune systems and the presence of tumour
antigens provoking an autoimmune response [3]. Treat-
ment of DM is empirical, often involving a combination
of steroids and immunomodulatory drugs [4]. Where
DM is associated with underlying malignancy, tumour
therapy may lead to the resolution of DM. Interestingly,Correspondence: petra.jurcic@gmail.com
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unless otherwise stated.a reverse relationship also exists, whereby a flare of DM
occurs with tumour recurrence - an association that is
demonstrated in this report [5].Case presentation
A 48-year-old female patient with history of skull fracture
suffered in a traffic accident 25 years ago presented in mid-
January 2014 in the infectology clinic of her local hospital
for facial, neck and ear erythema; butterfly-shaped rash;
pain in the upper arm muscles; stiffness of hands and dys-
phagia. Considering the sedimentation (SE) 30 creatine
kinase (CK) 308 result, as well as leukocyte (L) 11.4 (white
blood cells (WBC) differential percent neutrophils (% neu)
87, percent lymphocytes (% lymphs) 7.2, percent mono-
cytes (% monos) 5.9, percent eosinophils (% eos) 0), the pa-
tient was referred to immunology tests (anti-antinuclear
antibodies verified by indirect immunofluorescence (ANA
IIF) slightly positive and anti-double-strained DNA (anti-
dsDNA), anti-Ro/SSA antibodies (anti-SS-A52), anti-Ro/
SSA antibodies (anti-SS-A60), SSB/La antibody (anti-SSB),
anti-Sm antibodies directed against 7 proteins (anti-Sm),
autoantibodies directed against the RNP/Sm ribonucleo-
protein complex (anti-Sm/RNP), anti-DNA topoisomerase
1 antibody (anti-DNA-topo 1), antibody directed against
Jo-1 protein (anti-Jo-1), CENP-B specific anti-centromerean Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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P (anti-RIBO P) negative). Since the administered cortico-
steroid treatment yielded no improvement, a multi-slice
computed tomography (MSCT) of the abdomen (Figure 1)
was performed, showing a pronounced thickening of the
cholecyst wall ranging from 11 to 17 millimeters (mm),
scattered and eccentric in appearance; two intraluminally
present choleliths, one within the fundus 18 × 16 mm and
the other infundibular 22 × 16 mm; and no evident peri-
cholecystic edema. The tumour markers are carcinoem-
bryonic antigen (CEA) 0.7 μg/l and carbohydrate antigen
19-9 (CA 19-9) 964 U/ml. Laparoscopically visualized
gallbladder showed malign alterations. Urgent cytological
analysis showed malign cells, after which the procedure
was reverted to laparotomy which verified omentum
carcinomatosis, as well as infiltration of the fifth liver seg-
ment. Palpable lymph nodes were in the direction of the
hepatoduodenal ligament. The procedure was finished with
exploration. Final histopathology report of the omentum
was adenocarcinoma (diffuse solid clusters of polymorph-
ous atypical hyperchromatic tumour cells and gland forma-
tions with atypical mucous-cylindrical epithelium).
Oncologist suggested treatment with cisplatin 25 mg/m2
(per square meter of body-surface area) and gemcitabine
1,000 mg/m2, each administered on days 1 and 8 and re-
peated every 21 days for up to 6 cycles, unless disease pro-
gression or unacceptable toxicity occurs. Prior to starting
chemotherapy in March 2014, the dermatologist increasedFigure 1 Preoperative MSCT of the abdomen and the pelvis.the corticosteroid dosage (methylprednisolone 60 mg/day)
due to newly manifested periorbital edema and macular
exanthem in the regions of the trunk, neck and dorsum of
the hand (Figures 2 and 3). The patient refused the recom-
mended skin biopsy. Still, there was some improvement in
muscular strength.
Prior to the first cycle of chemotherapy, the patient was
given two doses of erythrocyte concentrate for normocytic
anaemia (haemoglobin (Hgb) 95 g/l, haematocrit (Ht)
0.345 l/l, mean corpuscular volume (MCV) 82.8 fl). After
10 days of high-dose corticosteroid therapy, the skin
eruptions faded. During and after the second cycle
of chemotherapy, the patient complained of general
weariness and fatigue.
After 3 cycles of chemotherapy, new skin changes devel-
oped on the right upper arm and both thighs, with perior-
bital edema more pronounced on the left side, despite the
32 mg/day maintenance dose of methylprednisolone. A
follow-up MSCT of the abdomen showed a 12-mm thick-
ening of the cholecyst wall - a regression, compared to the
initial MSCT result - and increased tumour marker levels
(CEA 1.6 μg/l, CA 19-9 2,525 U/ml). During the next
three chemotherapy cycles, additional skin changes mani-
fested in the armpit and on the scalp; some marker levels
also increased (CA 19-9 3,259 U/ml; the gamma-glutamyl
transferase (GGT) doubled). Final MSCT of the thorax,
abdomen and pelvis was performed after treatment com-
pletion in August 2014, showing a progression of hepatic
Figure 2 Periorbital edema and macular exanthem of the face.
Figure 3 Gottron’s papules on the metacarpophalangeal and
interphalangeal joints.
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to palliative care.
The patient presented in the case report was treated
using the standard care of gall bladder carcinoma. The
Helsinki Declaration was obeyed. Ethical board of Hospital
Sisters of Charity gave the approval.
Discussion
Gallbladder carcinoma is the most common and the
most malignant tumour of the biliary tract. It occurs
mostly between the ages of 60 and 70 and is 2 to 6 times
more common in women. Histologically, 95% of
gallbladder carcinoma patients have adenocarcinoma;
this was also the case with my patient, as the final histo-
pathology report of the omentum showed. Interestingly,
the patient was not aware of her long-standing cholelith-
iasis and had no pathological condition connected to
increased risk.
Gallbladder carcinoma has an extremely bleak prognosis;
only 5% to 10% of patients who undergo surgery are likely
to survive the following 5 years [6]. Also, one third of pa-
tients whose surgery is finished with exploration show
peritoneal and liver metastases that were not visible on
MSCT or MRI. In cases of suspected disseminated malig-
nant disease, diagnostic laparoscopy is recommended [7].
My patient’s preoperative CT of the thorax, abdomen and
pelvis showed no sign of liver or peritoneal metastases.
Although skin biopsy was not performed on my patient
and although she did not test positive for autoantibodies
usually present in patients suffering from dermatomyositis,
it is my opinion that her clinical presentation is consistent
with paraneoplastic dermatomyositis. The patient under-
went chemotherapy with cisplatin and gemcitabine, which
was in accordance with the results of the study of phase III
of patients with advanced or metastatic carcinoma. Adding
cisplatin to gemcitabine, that is its interaction between
gemcitabine and cisplatin afforded significant progression-
free survival (median, 8.4 versus 6.5 months; hazard ratio
(HR), 0.72; 95% confidence interval (CI), 0.57 to 0.90;
p = .003) and overall survival benefits (median, 11.7 versus
8.3 months; HR, 0.70; 95% CI, 0.54 to 0.89; p = .002). The
most common side effects include decreased WBC count
and fatigue [8]. My patient never exhibited decreased
WBC count, which was partly due to the effects of cortico-
steroid therapy. Since receiving the second cycle of chemo-
therapy, she complained of increased general weariness
and fatigue, which could be due to the chemotherapy
treatment.
In January 2015, I searched PubMed for terms gallblad-
der cancer, gallbladder carcinoma and dermatomyositis
and found a total of six case reports in English describing
dermatomyositis in patients suffering from gallbladder
carcinoma [9-13]. All of the cases featured female patients
over 44 years of age, some with present risk factors
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the appearance of dermatomyositis and malignant disease
ranged from 2 weeks to 2 years. Considering the patient
was initially treated in a relatively small facility and the
administered treatment did not lead to improvement of
her condition, it was soon suspected she had a malignant
disease.
In the cases I studied, malignant disease was diagnosed
within 2 to 7 months.
My patient initially had elevated CK, slightly positive
ANA IIF and negative anti-Jo-1, as described in other pa-
tients. The tumour markers were initially determined to be
CEA and CA 19-9. CEA was within range, whereas CA
19-9 was 24 times above normal. Elevated serum CEA and
CA 19-9 levels could be suggestive of gallbladder cancer,
bearing in mind that CA 19-9 has higher specificity, and
CEA a higher sensitivity [14]. Although some authors de-
scribe a complete regression of skin changes following ad-
equate treatment, in the case of my patient, the
dermatomyositis and the malignant disease progressed in-
dependently of one another [13]. Following high-dose cor-
ticosteroid therapy, the skin changes faded within the same
period as described in the case report of another patient;
however, after 3 cycles of maintenance therapy, they pro-
gressed, although the radiology report verified the regres-
sion of the disease.
Conclusions
Gall bladder carcinoma should be added to the list of
malignancies with dermatomyositis and has to be ex-
cluded by relevant investigation in women, especially
since an inexpensive, simple and easily available initial
testing exists - abdomen sonography.
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